Check-Cap Ltd (7CC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Check-Cap Ltd (7CC) has a cash flow conversion efficiency ratio of -0.149x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.54 Million ≈ $-4.14 Million USD) by net assets (€23.69 Million ≈ $27.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Check-Cap Ltd (7CC) balance sheet quality index to measure how much of total assets are equity-financed.
Check-Cap Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Check-Cap Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Check-Cap Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Check-Cap Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Check-Cap Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
U-BX Technology Ltd. Ordinary Shares
NASDAQ:UBXG
|
-0.017x |
|
Lodestar Minerals Ltd
AU:LSR
|
3.339x |
|
Zwahlen et Mayr SA
SW:ZWM
|
-0.106x |
|
Precise Biometrics AB
ST:PREC
|
0.031x |
|
Mex Polska S.A.
WAR:MEX
|
0.244x |
|
Culpeo Minerals Ltd
AU:CPO
|
-0.105x |
|
Ictsi Jasa Prima Tbk
JK:KARW
|
0.015x |
|
Lincoln Mining Corp
V:LMG
|
0.119x |
Annual Cash Flow Conversion Efficiency for Check-Cap Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Check-Cap Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 7CC stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.44 Million ≈ $4.02 Million |
€-46.00K ≈ $-53.78K |
-0.013x | -100.24% |
| 2024-12-31 | €-1.45 Million ≈ $-1.70 Million |
€-8.00 Million ≈ $-9.36 Million |
5.520x | +871.22% |
| 2023-12-31 | €23.69 Million ≈ $27.69 Million |
€-16.95 Million ≈ $-19.82 Million |
-0.716x | -58.06% |
| 2022-12-31 | €41.31 Million ≈ $48.30 Million |
€-18.71 Million ≈ $-21.87 Million |
-0.453x | -41.13% |
| 2021-12-31 | €50.69 Million ≈ $59.26 Million |
€-16.26 Million ≈ $-19.01 Million |
-0.321x | +59.93% |
| 2020-12-31 | €16.38 Million ≈ $19.15 Million |
€-13.11 Million ≈ $-15.33 Million |
-0.801x | +61.14% |
| 2019-12-31 | €6.23 Million ≈ $7.29 Million |
€-12.84 Million ≈ $-15.01 Million |
-2.060x | -165.41% |
| 2018-12-31 | €13.03 Million ≈ $15.23 Million |
€-10.11 Million ≈ $-11.82 Million |
-0.776x | +48.99% |
| 2017-12-31 | €5.91 Million ≈ $6.90 Million |
€-8.99 Million ≈ $-10.51 Million |
-1.522x | -99.89% |
| 2016-12-31 | €10.41 Million ≈ $12.17 Million |
€-7.92 Million ≈ $-9.26 Million |
-0.761x | -- |
About Check-Cap Ltd
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.